Abstract
Although thalidomide has been reported to be useful for treating refractory cutaneous lupus erythematosus (CLE), reports of its toxicity have limited its use in many clinical practices. Investigators of this open-label study examined response to thalidomide in 60 patients treated over an 18-year period and measured disease activity with the validated cutaneous lupus erythematosus disease area and severity index (CLASI) scoring …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
